Free Trial
NASDAQ:PMVP

PMV Pharmaceuticals Q4 2023 Earnings Report

PMV Pharmaceuticals logo
$1.07 -0.01 (-0.93%)
Closing price 04:00 PM Eastern
Extended Trading
$1.07 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, February 29, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

PMV Pharmaceuticals' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

PMV Pharmaceuticals Earnings Headlines

Most Americans have no idea this plan exists...
A Dollar Crash Is Coming - Here's When It Could Happen Already in 2025, the U.S. dollar has lost more value than in ANY year since Lehman's collapse. Meanwhile, bonds are falling... gold and silver are soaring... and bitcoin has risen over $100,000. Now, one analyst who predicted the 2008 crisis and recommended shorting Lehman for an 82% return in just five months explains why you need to get OUT of cash and exactly where to move your money instead.
PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile

More Earnings Resources from MarketBeat